Skip to main content
  • Saved

Emerging agents and regimens for multiple myeloma

Emerging agents and regimens for multiple myeloma

Source : https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00980-5

The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development.